PMID- 1329478
OWN - NLM
STAT- MEDLINE
DCOM- 19921029
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 70
IP  - 10
DP  - 1992 Oct 8
TI  - Comparison of treatment with lisinopril versus enalapril for congestive heart 
      failure.
PG  - 78C-83C
AB  - The effect of lisinopril 5-20 mg once daily or enalapril 5-20 mg once daily on 
      exercise capacity, ventricular ectopic activity, and signs and symptoms of heart 
      failure have been studied in 278 patients with mild-to-moderate (New York Heart 
      Association [NYHA] classes II and III) heart failure in a randomized, 
      double-blind, parallel-group study of 12 weeks' duration. Exercise duration was 
      significantly increased by both angiotensin-converting enzyme (ACE) inhibitors 
      after 6 and 12 weeks of treatment compared with their respective baseline values. 
      There was a trend toward a greater increase in exercise duration on lisinopril 
      after 12 weeks, although this did not reach statistical significance (p = 
      0.0748). There were no significant treatment differences with respect to the 
      effect of the 2 drugs on ventricular ectopic counts, couplets, or nonsustained 
      ventricular tachycardia. Both drugs were equally effective in improving NYHA 
      grading and symptoms. Neither treatment had any significant effect on mean heart 
      rate or mean blood pressures. Both treatments were equally well tolerated. The 
      most commonly reported adverse events on both drugs were cough, dizziness, fall 
      in blood pressure, vertigo, and myocardial infarction. The results of this study 
      indicate that lisinopril 5-20 mg once daily is at least as effective and well 
      tolerated as enalapril 5-20 mg once daily.
FAU - Zannad, F
AU  - Zannad F
AD  - Department of Cardiology, Hopital Central, Nancy, France.
FAU - van den Broek, S A
AU  - van den Broek SA
FAU - Bory, M
AU  - Bory M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Dipeptides)
RN  - 0 (Placebos)
RN  - 69PN84IO1A (Enalapril)
RN  - E7199S1YWR (Lisinopril)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Arrhythmias, Cardiac/physiopathology/prevention & control
MH  - Blood Pressure/drug effects
MH  - Dipeptides/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Electrocardiography, Ambulatory/drug effects
MH  - Enalapril/administration & dosage/adverse effects/*therapeutic use
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Lisinopril
MH  - Male
MH  - Middle Aged
MH  - Physical Exertion/drug effects
MH  - Placebos
MH  - Potassium/blood
EDAT- 1992/10/08 00:00
MHDA- 1992/10/08 00:01
CRDT- 1992/10/08 00:00
PHST- 1992/10/08 00:00 [pubmed]
PHST- 1992/10/08 00:01 [medline]
PHST- 1992/10/08 00:00 [entrez]
AID - 0002-9149(92)91362-8 [pii]
AID - 10.1016/0002-9149(92)91362-8 [doi]
PST - ppublish
SO  - Am J Cardiol. 1992 Oct 8;70(10):78C-83C. doi: 10.1016/0002-9149(92)91362-8.